Intracranial	intracranial	O	O	O	O
pressure	pressure	O	O	O	O
increases	increases	O	O	O	O
during	during	O	O	O	O
alfentanil-induced	alfentanil-induced	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Intracranial	intracranial	O	O	O	O
pressure	pressure	O	O	O	O
(	(	O	O	O	O
ICP	icp	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
measured	measured	O	O	O	O
during	during	O	O	O	O
alfentanil-induced	alfentanil-induced	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
in	in	O	O	O	O
rats	rats	O	O	O	O
.	.	O	O	O	O

Ten	ten	O	O	O	O
rats	rats	O	O	O	O
had	had	O	O	O	O
arterial	arterial	O	O	O	O
,	,	O	O	O	O
central	central	O	O	O	O
venous	venous	O	O	O	O
(	(	O	O	O	O
CVP	cvp	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
subdural	subdural	O	O	O	O
cannulae	cannulae	O	O	O	O
inserted	inserted	O	O	O	O
under	under	O	O	O	O
halothane	halothane	CHEMICALS	O	OTHERS	I
anesthesia	anesthesia	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
animals	animals	O	O	O	O
were	were	O	O	O	O
mechanically	mechanically	O	O	O	O
ventilated	ventilated	O	O	O	O
to	to	O	O	O	O
achieve	achieve	O	O	O	O
normocarbia	normocarbia	O	O	O	O
(	(	O	O	O	O
PCO2	pco2	O	O	O	O
=	=	O	O	O	O
42	42	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1	1	O	O	O	O
mmHg	mmhg	O	O	O	O
,	,	O	O	O	O
mean	mean	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
SE	se	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Following	following	O	O	O	O
instrumentation	instrumentation	O	O	O	O
,	,	O	O	O	O
halothane	halothane	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
discontinued	discontinued	O	O	O	O
and	and	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
125	125	O	O	O	O
mu/kg	mu/kg	O	O	O	O
)	)	O	O	O	O
administered	administered	O	O	O	O
iv	iv	O	O	O	O
during	during	O	O	O	O
emergence	emergence	O	O	O	O
from	from	O	O	O	O
halothane	halothane	CHEMICALS	O	OTHERS	I
anesthesia	anesthesia	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
five	five	O	O	O	O
rats	rats	O	O	O	O
that	that	O	O	O	O
developed	developed	O	O	O	O
somatic	somatic	O	O	OTHERS	I
rigidity	rigidity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
ICP	icp	O	O	O	O
and	and	O	O	O	O
CVP	cvp	O	O	O	O
increased	increased	O	O	O	O
significantly	significantly	O	O	O	O
above	above	O	O	O	O
baseline	baseline	O	O	O	O
(	(	O	O	O	O
delta	delta	O	O	O	O
ICP	icp	O	O	O	O
7.5	7.5	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.0	1.0	O	O	O	O
mmHg	mmhg	O	O	O	O
,	,	O	O	O	O
delta	delta	O	O	O	O
CVP	cvp	O	O	O	O
5.9	5.9	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.3	1.3	O	O	O	O
mmHg	mmhg	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
variables	variables	O	O	O	O
returned	returned	O	O	O	O
to	to	O	O	O	O
baseline	baseline	O	O	O	O
when	when	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
abolished	abolished	O	O	O	O
with	with	O	O	O	O
metocurine	metocurine	O	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
five	five	O	O	O	O
rats	rats	O	O	O	O
that	that	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
become	become	O	O	O	O
rigid	rigid	O	O	O	O
,	,	O	O	O	O
ICP	icp	O	O	O	O
and	and	O	O	O	O
CVP	cvp	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
change	change	O	O	O	O
following	following	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

These	these	O	O	O	O
observations	observations	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
rigidity	rigidity	O	DISEASE	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
prevented	prevented	O	O	O	O
when	when	O	O	O	O
alfentanil	alfentanil	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
,	,	O	O	O	O
presumably	presumably	O	O	O	O
,	,	O	O	O	O
other	other	O	O	O	O
opiates	opiates	O	O	O	O
,	,	O	O	O	O
are	are	O	O	O	O
used	used	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
anesthetic	anesthetic	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
ICP	icp	O	O	O	O
problems	problems	O	O	O	O
.	.	O	O	O	O

